​

Travere Therapeutics (TVTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TVTX Stock Forecast

Travere Therapeutics (TVTX) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $51.50, with a high of $54.00 and a low of $49.00. This represents a 15.11% increase from the last price of $44.74.

$5 $15 $25 $35 $45 $55 High: $54 Avg: $51.5 Low: $49 Last Closed Price: $44.74

TVTX Stock Rating

Travere Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (83.33%), 3 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 3 15 Strong Sell Sell Hold Buy Strong Buy

TVTX Price Target Upside V Benchmarks

TypeNameUpside
StockTravere Therapeutics15.11%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-24
Avg Price Target-$51.50$46.75
Last Closing Price$44.74$44.74$44.74
Upside/Downside-15.11%4.49%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 262121--15
Apr, 261122--15
Mar, 261122--15
Feb, 261122--15
Jan, 261122--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 14, 2026Piper Sandler$49.00$41.1119.19%9.52%
Apr 14, 2026Guggenheim$54.00$30.7075.90%20.70%
Jan 14, 2026Vamil DivanGuggenheim$49.00$28.3972.60%9.52%
Sep 10, 2025Maury RaycroftJefferies$35.00$27.3128.16%-21.77%
Oct 31, 2024Liisa BaykoEvercore ISI$33.00$17.5088.57%-26.24%
Oct 21, 2024Mohit BansalWells Fargo$27.00$17.8751.09%-39.65%
Oct 10, 2024Liisa BaykoEvercore ISI$30.00$18.0766.02%-32.95%
Oct 09, 2024Jason ZemanskyBank of America Securities$20.00$15.2131.49%-55.30%
Oct 01, 2024Carter GouldBarclays$18.00$13.9928.66%-59.77%
Sep 27, 2024Vamil DivanGuggenheim$23.00$15.0452.93%-48.59%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 05, 2026WedbushOutperformOutperformhold
May 05, 2026CitigroupBuyBuyhold
May 05, 2026H.C. WainwrightBuyBuyhold
Apr 24, 2026GuggenheimBuyBuyhold
Apr 14, 2026Piper SandlerNeutralOverweightupgrade
Apr 14, 2026WedbushOutperformOutperformhold
Apr 14, 2026CitigroupBuyBuyhold
Mar 23, 2026CitigroupBuyBuyhold
Feb 06, 2026Piper SandlerNeutralNeutralhold
Jan 14, 2026GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.01$-4.37$-1.50$-4.08$-0.29---
Avg Forecast$-3.01$-4.48$-1.62$-3.66$-1.13$0.60$1.11$1.88
High Forecast$-2.24$-3.17$-1.39$-3.54$-0.39$2.59$3.24$2.67
Low Forecast$-4.59$-6.86$-1.79$-3.82$-1.75$-0.64$0.40$0.70
Surprise %--2.46%-7.41%11.48%-74.34%---

Revenue Forecast

$100M $290M $480M $670M $860M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$131.84M$109.46M$145.24M$233.18M$490.73M---
Avg Forecast$225.72M$208.36M$195.51M$230.58M$342.48M$478.46M$630.10M$780.85M
High Forecast$316.57M$293.80M$198.06M$243.97M$415.94M$488.58M$833.66M$1.03B
Low Forecast$181.47M$161.65M$193.14M$220.79M$266.55M$468.34M$325.75M$403.68M
Surprise %-41.59%-47.47%-25.71%1.13%43.29%---

Net Income Forecast

$-500M $-350M $-200M $-50M $100M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-180.09M$-278.48M$-111.40M$-321.55M$-25.55M---
Avg Forecast$-142.95M$-176.32M$-376.33M$-273.28M$-113.69M$41.94M$117.12M$139.77M
High Forecast$-114.36M$-141.05M$-301.07M$-262.54M$-29.06M$191.99M$240.53M$198.47M
Low Forecast$-171.54M$-211.58M$-451.60M$-284.02M$-129.88M$-47.47M$29.42M$52.01M
Surprise %25.98%57.94%-70.40%17.66%-77.53%---

TVTX Forecast FAQ

Is Travere Therapeutics stock a buy?

Travere Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Travere Therapeutics is a favorable investment for most analysts.

What is Travere Therapeutics's price target?

Travere Therapeutics's price target, set by 18 Wall Street analysts, averages $51.5 over the next 12 months. The price target range spans from $49 at the low end to $54 at the high end, suggesting a potential 15.11% change from the previous closing price of $44.74.

How does Travere Therapeutics stock forecast compare to its benchmarks?

Travere Therapeutics's stock forecast shows a 15.11% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Travere Therapeutics over the past three months?

  • May 2026: 13.33% Strong Buy, 80.00% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 6.67% Strong Buy, 80.00% Buy, 13.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 6.67% Strong Buy, 80.00% Buy, 13.33% Hold, 0% Sell, 0% Strong Sell.

What is Travere Therapeutics’s EPS forecast?

Travere Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $0.6, marking a -306.90% decrease from the reported $-0.29 in 2025. Estimates for the following years are $1.11 in 2027, and $1.88 in 2028.

What is Travere Therapeutics’s revenue forecast?

Travere Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $478.46M, reflecting a -2.50% decrease from the reported $490.73M in 2025. The forecast for 2027 is $630.1M, and $780.85M for 2028.

What is Travere Therapeutics’s net income forecast?

Travere Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $41.94M, representing a -264.16% decrease from the reported $-25.546M in 2025. Projections indicate $117.12M in 2027, and $139.77M in 2028.